In future studies, we plan to stabilize Aff-MAG2 to avoid degradation, characterize its pharmacokinetic properties and its mechanism of action further through other biochemical and in cellulo methods, like microscopy-based approaches and test the efficacy of this novel cytotoxic construct in patient-derived xenograft AML models in vivo. The gene discussed is RETREG2; the disease is acute myeloid leukemia.